Investment analysts at Citizens Jmp started coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) in a report released on Tuesday, Benzinga reports. The brokerage set a “market outperform” rating and a $35.00 price target on the stock. Citizens Jmp’s target price would indicate a potential upside of 127.64% from the company’s current price.
AAPG has been the subject of several other research reports. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. JPMorgan Chase & Co. cut their price objective on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, October 8th. Finally, Citigroup started coverage on shares of Ascentage Pharma Group International in a research report on Tuesday. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and an average target price of $43.67.
Check Out Our Latest Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million during the quarter. On average, equities analysts anticipate that Ascentage Pharma Group International will post -2.42 earnings per share for the current year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- Ag Equipment’s Recovery Trade Meets Washington’s Scrutiny
- The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
- Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
- Salesforce Just Got a Rare Double Upgrade—What Changed?
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
